What is Chronic Obstructive Pulmonary Disease (COPD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities, usually caused by significant exposure to noxious particles or gases.

Definition and Characteristics

The disease is marked by symptoms such as dyspnea, cough, and/or sputum production, which are often underreported by patients 1. Tobacco smoking is the main risk exposure for COPD, but environmental exposures like biomass fuel exposure and air pollution may also contribute 1.

Key Points

  • COPD is a progressive lung disease with airflow limitation that is not fully reversible.
  • The clinical diagnosis of COPD is suggested by symptoms, but can only be established firmly by an objective measurement indicating airflow obstruction 1.
  • Appropriate treatment can lead to some improvement in both measured airflow obstruction and/or clinically important symptoms 1.

Management and Treatment

Treatment focuses on symptom management, reducing exacerbations, and slowing disease progression. For most patients, bronchodilators form the cornerstone of therapy, starting with short-acting agents like albuterol for mild symptoms. As the disease progresses, long-acting bronchodilators become necessary, including long-acting beta-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) 1.

Non-Pharmacological Interventions

Pulmonary rehabilitation, smoking cessation, annual influenza vaccination, and pneumococcal vaccination are essential non-pharmacological interventions. Oxygen therapy is recommended for patients with severe hypoxemia 1.

Disease Progression and Monitoring

COPD management requires a stepwise approach because the disease causes progressive airway inflammation and remodeling, leading to irreversible airflow limitation. Regular follow-up is crucial to monitor disease progression and adjust treatment accordingly 1.

From the FDA Drug Label

BREO ELLIPTA is a prescription medicine used to treat COPD COPD is a chronic lung disease that includes chronic bronchitis, emphysema, or both.

Chronic Obstructive Pulmonary Disease (COPD) is a chronic lung disease that includes chronic bronchitis, emphysema, or both 2.

From the Research

Definition of Chronic Obstructive Pulmonary Disease (COPD)

  • Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease characterized by obstructive and inflammatory components 3, 4
  • It is the leading cause of death worldwide, with cigarette smoking being the primary cause of COPD 5
  • The disease is marked by symptoms such as shortness of breath, wheezing, and coughing, which can worsen over time if left untreated 3, 4

Pathology and Progression of COPD

  • The pathology of COPD includes both obstructive and inflammatory components, which can lead to repeated injury and enhance the disease's progression 6, 4
  • Smoking cessation is the most effective strategy for slowing down the progression of COPD and reducing mortality 7, 6, 5
  • The combination of counseling and pharmacotherapy is more effective than either alone in promoting smoking cessation and sustained abstinence in smokers with COPD 7, 6

Treatment and Management of COPD

  • Treatment of moderate or severe COPD with combinations of inhaled corticosteroids, long-acting beta-agonists, and long-acting anticholinergic bronchodilators is common but requires careful consideration of the patient's individual needs 3
  • Vaccination against influenza and pneumococcus is an effective preventive strategy to prevent exacerbations in patients with COPD 6
  • The use of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol has been shown to improve lung function and symptom measures in patients with moderate to severe COPD 4

Related Questions

What is the current initial treatment for Chronic Obstructive Pulmonary Disease (COPD)?
Can AirSupra (albuterol) and Duoneb (ipratropium bromide and albuterol) be used together?
How to manage a 68-year-old smoker with cough and dyspnea?
What is the difference between Chronic Obstructive Pulmonary Disease (COPD) and Asthma?
What is the most appropriate additional therapy for a 62-year-old man with Chronic Obstructive Pulmonary Disease (COPD), who has a 40-pack-year smoking history, experiences breathlessness walking up a slight hill, and has an Forced Expiratory Volume in one second (FEV1) to Forced Vital Capacity (FVC) ratio of 0.58, with an FEV1 of 62% of predicted, currently treated with salmeterol (Serevent) and tiotropium (Spiriva)?
Can a patient take VTAMA (tapinarof) and opzelura (ruxolitinib) for psoriasis (PSO)?
Does alveolar bone grafting increase the risk of Medication-Related Osteonecrosis of the Jaw (MRONJ) in patients taking bisphosphonates?
What is the cause of a lower limb ulcer in a 90-year-old woman with essential thrombocytosis, treated with Aspirin (Acetylsalicylic Acid) and Hydroxyurea, who recently received Levofloxacin (Levaquin) for pneumonia and low molecular weight Heparin (HBPM) for thromboprophylaxis?
What is the treatment for atrial fibrillation (AFib) with rapid ventricular response (RVR)?
What medication should be added to the treatment regimen of a patient with Heart Failure with Reduced Ejection Fraction (HFrEF) and a left ventricular ejection fraction (LVEF) of 25%, currently experiencing dyspnea on exertion, and taking Aspirin (ASA), Carvedilol, Entresto (Sacubitril/Valsartan), Spironolactone, Furosemide, and Empagliflozin?
What is the next step in managing a patient with newly diagnosed sarcoidosis, presenting with dyspnea, hilar adenopathy on chest radiograph and thoracic scan, confirmed by biopsy, and electrocardiogram (ECG) showing first-degree atrioventricular (AV) block and bundle branch block (BBB), with no history of syncope and normal exercise tolerance test (ETT)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.